Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraventricular 5-Azacytidine for Recurrent Posterior Fossa Ependymoma
NCT03572530Phase 1Completed
- Sponsor
- UTHealth Houston
- Start
- Feb 2019
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of azacitidine in ependymoma (3 arms), sponsored by UTHealth Houston. Primary endpoint: Dose-Limiting Toxicity at 8 weeks. Started Feb 2019; status: completed.
02
Drugs
azacitidine
03
Conditions
ependymoma
Beyond the preview
Go deeper on NCT03572530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03572530.